Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)

X
Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 187004 CL (Primary)
  • Indications Obesity; Overweight; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 Dec 2022 Results (n=34) assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 187004 After Multiple Dosing Over 14 Days in male and female patients with type 2 diabetes and overweight or obesity published in the Experimental and Clinical Endocrinology and Diabetes
    • 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Jun 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top